Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Epidemiology and Surveillance

In Vivo Selection of Rifamycin-Resistant Clostridium difficile during Rifaximin Therapy

Robert J. Carman, James H. Boone, Harish Grover, Kimberly N. Wickham, Li Chen
Robert J. Carman
aTechLab, Inc., Blacksburg, Virginia, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James H. Boone
aTechLab, Inc., Blacksburg, Virginia, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Harish Grover
bCarilion Clinic Gastroenterology, Christiansburg, Virginia, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kimberly N. Wickham
aTechLab, Inc., Blacksburg, Virginia, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Li Chen
aTechLab, Inc., Blacksburg, Virginia, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.00974-12
  • Article
  • Info & Metrics
  • PDF
Loading

ABSTRACT

We report the selection of Clostridium difficile resistant to the rifamycin class of antibiotics in a patient within 32 h of receiving rifaximin for the treatment of recurrent C. difficile diarrhea. Resistance was associated with single nucleotide substitutions within rpoB.

TEXT

A 65-year-old male outpatient with an 18-month history of four earlier episodes of Clostridium difficile diarrhea, each treated with vancomycin, was diagnosed with a fifth episode. His symptoms began just 4 days after his last vancomycin treatment stopped. Rifaximin (200 mg three times a day) was begun 4 days later, on day 1 of this study. Neither fecal samples nor isolates from the earlier episodes were available for study.

This research was approved by TechLab, Inc., Institutional Review Board (IRB) number 1 (registration number IRB00003505, IRB organization number IORG0002905). On day 1, after giving his informed consent, the patient provided frequent fecal samples for research only. The results of the research tests we report were not used to support the patient's clinical diagnosis or guide treatment decisions. C. difficile spores were cultured on cycloserine-cefoxitin-fructose agar supplemented with sodium taurocholate. Four or five isolates from each sample were PCR ribotyped (9) and tested with Etest strips on brucella blood agar (7) for the MIC of rifampin (RIF). RIF and rifaximin are both members of the rifamycin class of antibiotics. Resistance to one indicates resistance to the other, and they may be used interchangeably when assaying MICs (8). rpoB1418-1812, the rifamycin resistance-determining region (RRDR) of each of the four or five isolates per sample, was sequenced (1, 2). All isolates were of ribotype 056. All produced toxins A and B. None produced binary toxin. All were susceptible to vancomycin and moxifloxacin.

On day 1, only sensitive (RIF MIC, 0.002 μg/ml) isolates with a wild-type RRDR were recovered. Exposure to rifaximin led rapidly to the emergence of resistance, and within 32 h, only resistant (RIF MIC, ≥32 μg/ml) isolates were found. The isolates had a C1506→T substitution in rpoB, a single nucleotide polymorphism (SNP) resulting in the His502Tyr change seen in resistant C. difficile (8). As treatment continued, only resistant strains of ribotype 056 were seen, the original strain and a second strain with the C1506→T substitution plus an additional C1488→T substitution that encodes Pro496Ser. This second SNP within rpoB of C. difficile has not been reported before (7, 8). Its effect on resistance is unknown. The patient was asymptomatic for about 2 weeks after taking rifaximin, although throughout that time, both strains of resistant ribotype 056 isolates persisted. Ribotype 056 isolates are not frequent in our studies (<2% of almost 2,000 isolates), nor does ribotype 056 RIF resistance appear widespread. These are the only RIF-resistant members of ribotype 056 in our collection of 41 isolates.

On day 49, when the two resistant strains were still present, the diarrhea returned and 1 week later, a 10-day course of fidaxomicin was given and the patient's diarrhea resolved. There was no other antibiotic exposure at that time. All of the research assays for C. difficile (culture, cytotoxicity, toxin, and glutamate dehydrogenase immunoassays, and reverse transcription-PCR assays for tcdB and for tpi, which encodes triphosphate isomerase, a metabolic enzyme [5]) were negative for nearly a week, but then the patient had >30 days of asymptomatic colonization by susceptible ribotype 056 isolates (RIF MIC, 0.002 μg/ml). Since he was diarrhea free, however, antimicrobial therapy was not implemented. The reappearance of RIF-sensitive ribotype 056 isolates probably occurred because the patient, susceptible to postantibiotic colonization, picked up spores shed into his home environment during much earlier episodes of diarrhea or, despite our negative findings (see above), because of its emergence from a persistent but inapparent level within the colon to one of abundance. The reversion of both resistant strains to the wild type seems less probable, particularly in the strain with two rpoB SNPs.

Despite the long absence of diarrhea, the patient again experienced discomfort and soft stools on day 232, although he did not consider himself to have diarrhea. Culture yielded a RIF-sensitive C. difficile isolate of ribotype 005, a toxigenic ribotype, new to the patient since we began monitoring him. Antibiotics were not considered. He remains, as of day 324, asymptomatically colonized with ribotype 005 bacteria.

RIF-resistant ribotype 056 isolates were recovered within 24 h of treatment. The rapid emergence of C. difficile with SNP-mediated fluoroquinolone resistance in a patient receiving both ciprofloxacin and levofloxacin is a similar example of the selection of resistant C. difficile during antimicrobial exposure (6). Rifaximin therapy for C. difficile diarrhea, especially for recurring cases, has been endorsed (3) and may become more common. If so, we might see the emergence of resistant isolates of ribotype 056 (or of any other toxigenic ribotype acquiring resistance to RIF) along the lines of the recent surge in the incidence of moxifloxacin-resistant ribotype 027 isolates. In fact, instances of RIF-resistant C. difficile associated with rifaximin therapy have been seen (4), while the incidence of resistance, largely confined to the equivalent of ribotype 027 isolates, has doubled at one institute (from <40 to >80%) in 4 years (3). While a RIF MIC of ≥32 μg/ml may not mean a lack of efficacy, since rifaximin reaches very high concentrations in the stool (up to 8,000 μg/g), antibiotic resistance plays a continuing and significant role in the biology of C. difficile.

ACKNOWLEDGMENTS

R.J.C., J.H.B., K.N.W., and L.C. are employees of TechLab, Inc. H.G. has no conflict of interest to declare.

FOOTNOTES

    • Received 10 May 2012.
    • Returned for modification 13 June 2012.
    • Accepted 16 August 2012.
    • Accepted manuscript posted online 20 August 2012.
  • Copyright © 2012, American Society for Microbiology. All Rights Reserved.

REFERENCES

  1. 1.↵
    1. Aubry-Damon H,
    2. Soussy CJ,
    3. Courvalin P
    . 1998. Characterization of mutations in the rpoB gene that confer rifampin resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 42:2590–2594.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Curry SR,
    2. et al
    . 2009. High frequency of rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital. Clin. Infect. Dis. 48:425–429.
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    1. Garey KW,
    2. et al
    . 2011. A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. J. Antimicrob. Chemother. 66:2850–2855.
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    1. Johnson S,
    2. et al
    . 2009. Rifaximin redux: treatment of recurrent Clostridium difficile infections with rifaximin immediately post-vancomycin treatment. Anaerobe 15:290–291.
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    1. Lemee L,
    2. et al
    . 2004. Multiplex PCR targeting tpi (triose phosphate isomerase), tcdA (toxin A), and tcdB (toxin B) genes for toxigenic culture of Clostridium difficile. J. Clin. Microbiol. 42:5710–5714.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Mena A,
    2. et al
    . 2012. In vivo selection of moxifloxacin-resistant Clostridium difficile. Antimicrob. Agents Chemother. 56:2788–2789.
    OpenUrlFREE Full Text
  7. 7.↵
    1. Miller MA,
    2. Blanchette R,
    3. Spigaglia P,
    4. Barbanti F,
    5. Mastrantonio P
    . 2011. Divergent rifamycin susceptibilities of Clostridium difficile strains in Canada and Italy and predictive accuracy of rifampin Etest for rifamycin resistance. J. Clin. Microbiol. 49:4319–4321.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. O'Connor JR,
    2. et al
    . 2008. Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile. Antimicrob. Agents Chemother. 52:2813–2817.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Stubbs SL,
    2. Brazier JS,
    3. O'Neill GL,
    4. Duerden BI
    . 1999. PCR targeted to the 16S-23S rRNA gene intergenic spacer region of Clostridium difficile and construction of a library consisting of 116 different PCR ribotypes. J. Clin. Microbiol. 37:461–463.
    OpenUrlAbstract/FREE Full Text
View Abstract
PreviousNext
Back to top
Download PDF
Citation Tools
In Vivo Selection of Rifamycin-Resistant Clostridium difficile during Rifaximin Therapy
Robert J. Carman, James H. Boone, Harish Grover, Kimberly N. Wickham, Li Chen
Antimicrobial Agents and Chemotherapy Oct 2012, 56 (11) 6019-6020; DOI: 10.1128/AAC.00974-12

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
In Vivo Selection of Rifamycin-Resistant Clostridium difficile during Rifaximin Therapy
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
In Vivo Selection of Rifamycin-Resistant Clostridium difficile during Rifaximin Therapy
Robert J. Carman, James H. Boone, Harish Grover, Kimberly N. Wickham, Li Chen
Antimicrobial Agents and Chemotherapy Oct 2012, 56 (11) 6019-6020; DOI: 10.1128/AAC.00974-12
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • TEXT
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Info & Metrics
  • PDF

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596